MedinCell announces successful completion of patient enrollment in the Phase 3 study of F14 (mdc-CWM), a first-in-class therapy for localized pain relief after Total knee replacement
August 31, 2023
August 31, 2023
Participation terms in the Combined General Meeting
August 21, 2023
August 21, 2023
MedinCell’s partner Teva announces successful launch of UZEDY™
August 2, 2023
August 2, 2023
MedinCell has received the last tranche of €10m from the European Investment Bank (EIB) loan
July 31, 2023
July 31, 2023
MedinCell announces its full year financial results April 2022 – March 2023
June 26, 2023
June 26, 2023
MedinCell will publish its annual results (April 2022-March 2023) on June 26, 2023
Phase 1 data of mdc-TJK investigational long-acting injectable of olanzapine for schizophrenia patients, exhibited favorable characteristics of an extended-release profile
May 22, 2023
May 22, 2023
MedinCell announces the successful pricing of its Global Offering and raises €25 million
May 12, 2023
May 12, 2023
MedinCell launches a Global Offering for approximately 25 million euros
May 11, 2023
May 11, 2023
MedinCell: mdc-TJK’s (Teva’s codename: TEV-44749) Phase 1 study pharmacokinetics to be presented for the first time by Teva at SIRS 2023 (May 11-15, 2023, Toronto, Canada)
May 4, 2023
May 4, 2023
First FDA approval and US commercial launch, MedinCell enters new era
May 2, 2023
May 2, 2023
Contacts
Medincell
David Heuzé
Head of Corporate and Financial Communications, and ESG
